США - англійська - NLM (National Library of Medicine)

bryant ranch prepack - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 10 mg - hydrocortisone tablets are indicated in the following conditions. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus systemic dermatomyositis (polymyositis) acute rheumatic

США - англійська - NLM (National Library of Medicine)

recombinetics, inc. - 1. ossabow miniature pig with rdna construct pcsk-d374y inserted into col21a1 locus on chromosome 7 (unii: fz8d40uq9w) (1. ossabow miniature pig with rdna construct pcsk-d374y inserted into col21a1 locus on chromosome 7 - unii:fz8d40uq9w), 2. ossabow miniature pig with rdna construct pcsk-d374y inserted into cdtsp2-atp23 intergenic locus on chromosome 5 (unii: g4s6j19kxs) (2. ossabow miniature pig with rdna construct pcsk-d374y inserted into cdtsp2-atp23 intergenic locus on chromosome 5 - unii:g4s6j19kxs) - 1. ossabow miniature pig with rdna construct pcsk-d374y inserted into col21a1 locus on chromosome 7 1 [arb'u] in 1 [arb'u] - limitations: the pcsk9 cdna used in this model was derived from chimpanzee and codon optimized to swine. since chimp and human pcsk9 are highly conserved (685/ 692 residues) most protein inhibitors will cross-react. however, due to the codon optimization, rnai therapy could only be evaluated with custom targets as demonstrated in rodents and non-human primates. product use: model animals and/or materials derived from these animals are intended for purchase only under license agreement with recombinetics, inc., and solely for use in connection with the specific licensed biomedical research. conditions of use: this model animal and any products derived from it are for biomedical research purposes only and not for use in humans. this is an investigational animal. edible products of investigational animals are not to be used for food unless authorization has been granted by the u.s. food and drug administration or by the u.s. department of agriculture.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - midostaurin 25mg - soft gelatin capsule - 25 mg - active: midostaurin 25mg excipient: corn oil, ethoxylated dl-alpha tocopherol ethanol gelatin glycerol iron oxide red iron oxide yellow macrogol 400 peg-40 castor oil purified water red printing ink (catalent) titanium dioxide - rydapt® is indicated: · in combination with standard anthracycline and cytarabine induction and cytarabine consolidation chemotherapy, followed in patients in complete response by single agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive · for the treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated haematological neoplasms (sm-ahn), or mast cell leukaemia (mcl).

Вірменія - англійська - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

abbott biologicals b.v. veerweg 12 - influenza vaccine inactivated (surface antigen)-a/brisbane/02/2018 (h1n1) pdm-like strain (a/brisbane/02/2018, ivr-190), a/kansas/14/2017 (h3n2)-like strain (a/ a/kansas/14/2017, nymc x-327), b/colorado/06/2017-like strain (b/ victoria/2/87/ lineage) (b/maryland/15/2016, nymc bx-69 a) - suspension for injection - 15mcg haemagglutinin/dose+ 15mcg haemagglutinin/dose+ 15mcg haemagglutinin/dose

Саудівська Аравія - англійська - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

abbott biologicals, netherlands - a/victoria/2570/2019 (h1n1)pdm09- like virus,a/darwin/9/2021 (h3n2)-like virus,b/austria/1359417/2021 (b/victoria lineage)-like virus - solution - 15,15,15 µg,

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 60ug (a/michigan/45/2015, x-275); influenza virus a/singapore/infimh-16-0019/2016 (h3n2) - like strain 60ug (a/singapore/infimh-16-0019/2016, nib-104); influenza virus b/phuket/3073/2013 - like strain 60ug (b/phuket/3073/2013 (yamagata lineage)) - suspension for injection - 180 mcg/dose - active: influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 60ug (a/michigan/45/2015, x-275) influenza virus a/singapore/infimh-16-0019/2016 (h3n2) - like strain 60ug (a/singapore/infimh-16-0019/2016, nib-104) influenza virus b/phuket/3073/2013 - like strain 60ug (b/phuket/3073/2013 (yamagata lineage)) excipient: dibasic sodium phosphate monobasic sodium phosphate octoxinol 9 sodium chloride water for injection - for active immunisation against influenza disease caused by influenza virus subtypes a and type b contained in the vaccine for use in persons 65 years of age and older.

Європейський Союз - англійська - EMA (European Medicines Agency)

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - influenza, human - vaccines - supemtek is indicated for active immunization for the prevention of influenza disease in adults.supemtek should be used in accordance with official recommendations.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1)pdm09-like virus (a/victoria/4897/2022 (ivr-238))); influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like virus (a/thailand/8/2022 (ivr-237))); influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021(b/victoria lineage)-like virus (b/austria/1359417/2021 (bvr-26))); influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013-like virus (b/phuket/3073/2013 bvr-1b)) - suspension for injection - 60 mcg/0.5ml - active: influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1)pdm09-like virus (a/victoria/4897/2022 (ivr-238))) influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like virus (a/thailand/8/2022 (ivr-237))) influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021(b/victoria lineage)-like virus (b/austria/1359417/2021 (bvr-26))) influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013-like virus (b/phuket/3073/2013 bvr-1b)) excipient: calcium chloride dihydrate citric acid monohydrate dibasic sodium phosphate dihydrate magnesium chloride hexahydrate monobasic potassium phosphate polysorbate 80 potassium chloride sodium chloride sodium citrate dihydrate sorbitan trioleate squalene water for injection - active immunisation against influenza in persons 65 years of age and older.

Саудівська Аравія - англійська - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

glaxo saudi arabia ltd, saudi arabia - monovalent inactivated spilit virion ah 1n1,monovalent inactivated spilit virion ah 3n2,monovalent inactivated spilit virion b strain victoria lineage,monovalent inactivated spilit virion b strain yamagate lineage - suspension for injection - 15,15,15,15 µg,

Канада - англійська - Health Canada

glaxosmithkline inc - sotrovimab - solution - 500mg - sotrovimab 500mg - monoclonal antibodies